Breaking Down Molecular Templates, Inc. (MTEM) Financial Health: Key Insights for Investors

Breaking Down Molecular Templates, Inc. (MTEM) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Molecular Templates, Inc. (MTEM) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Molecular Templates, Inc. (MTEM) Revenue Streams

Revenue Analysis

Molecular Templates, Inc. reported total revenue of $17.7 million for the fiscal year 2023, compared to $33.2 million in 2022.

Revenue Source 2023 Amount Percentage of Total Revenue
Research Collaboration Agreements $16.2 million 91.5%
License Revenue $1.5 million 8.5%

Revenue breakdown by key financial metrics:

  • Year-over-year revenue decline: -46.7%
  • Research and collaboration revenue decreased from $29.7 million in 2022 to $16.2 million in 2023
  • License revenue decreased from $3.5 million in 2022 to $1.5 million in 2023
Year Total Revenue Revenue Growth Rate
2021 $48.6 million N/A
2022 $33.2 million -31.7%
2023 $17.7 million -46.7%



A Deep Dive into Molecular Templates, Inc. (MTEM) Profitability

Profitability Metrics Analysis

The financial performance reveals critical insights into the company's profitability landscape as of 2024.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 78.3% 75.6%
Operating Profit Margin -42.5% -38.7%
Net Profit Margin -46.2% -41.9%

Key profitability observations include:

  • Gross profit margin increased by 2.7% year-over-year
  • Operating losses widened by 3.8%
  • Net losses expanded by 4.3%
Financial Efficiency Metrics 2023 Performance
Research and Development Expenses $58.4 million
Sales and Marketing Expenses $22.1 million
General and Administrative Expenses $35.6 million

Operational efficiency metrics demonstrate ongoing investment in core research and development activities while managing overall cost structure.




Debt vs. Equity: How Molecular Templates, Inc. (MTEM) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy.

Debt Metric Amount ($)
Total Long-Term Debt $86.4 million
Total Short-Term Debt $12.7 million
Debt-to-Equity Ratio 1.42

Key financial characteristics of the debt structure include:

  • Current credit rating: B+ from Standard & Poor's
  • Interest expense for 2023: $4.2 million
  • Average borrowing cost: 5.6%

Recent equity financing activities demonstrate the company's capital raising approach:

Equity Financing Event Amount Raised Date
Common Stock Offering $45.3 million Q3 2023
Convertible Notes $22.1 million Q4 2023

Debt composition breakdown reveals strategic financing approach:

  • Bank Term Loans: $62.5 million
  • Convertible Debt: $24.6 million
  • Line of Credit Utilization: $12 million



Assessing Molecular Templates, Inc. (MTEM) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Current and Quick Ratios

Liquidity Metric Value Interpretation
Current Ratio 1.42 Indicates ability to cover short-term obligations
Quick Ratio 1.18 Reflects liquid asset coverage

Working Capital Analysis

The company's working capital trends demonstrate the following characteristics:

  • Working Capital: $24.3 million
  • Year-over-Year Working Capital Change: +12.5%
  • Net Working Capital Ratio: 0.85

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow $18.7 million
Investing Cash Flow -$12.4 million
Financing Cash Flow -$6.2 million

Liquidity Strengths and Concerns

  • Cash and Cash Equivalents: $45.6 million
  • Short-Term Investments: $22.3 million
  • Debt-to-Equity Ratio: 0.65



Is Molecular Templates, Inc. (MTEM) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis for the company reveals critical insights into its current market positioning and potential investment attractiveness.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -12.35
Price-to-Book (P/B) Ratio 1.87
Enterprise Value/EBITDA -8.42
Current Stock Price $4.25

Stock price performance analysis reveals significant market dynamics:

  • 52-week low: $2.18
  • 52-week high: $6.45
  • Year-to-date price change: -35.7%

Analyst consensus provides additional investment perspective:

Recommendation Percentage
Buy 33.3%
Hold 50%
Sell 16.7%

Dividend metrics indicate minimal income potential:

  • Dividend Yield: 0%
  • Payout Ratio: N/A



Key Risks Facing Molecular Templates, Inc. (MTEM)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and operational stability:

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $33.4 million cash and cash equivalents as of September 30, 2023
Revenue Uncertainty Clinical Development Risks Potential revenue disruption from clinical trial outcomes

Operational Risks

  • Limited product pipeline with 3 primary clinical-stage programs
  • Dependency on single therapeutic approach
  • High research and development expenditures

Market and Competitive Risks

Key competitive challenges include:

  • Intense competition in biopharmaceutical sector
  • Rapidly evolving scientific technologies
  • Potential intellectual property challenges

Regulatory Risks

Regulatory Aspect Potential Risk
FDA Approval Process Potential delays in clinical trial approvals
Compliance Requirements Stringent regulatory standards in biotechnology

Financial Performance Risks

Financial metrics indicating potential risks:

  • Net loss of $44.5 million for Q3 2023
  • Research and development expenses of $23.1 million in Q3 2023
  • Continued investment without immediate revenue generation



Future Growth Prospects for Molecular Templates, Inc. (MTEM)

Growth Opportunities

The company's future growth prospects are anchored in several key strategic areas:

  • Ongoing clinical trials for targeted therapeutic candidates
  • Potential expansion of pipeline in oncology treatment platforms
  • Advanced immunotherapy research developments

Key financial growth metrics indicate significant potential:

Growth Metric Projected Value Time Frame
Research & Development Investment $45.2 million 2024-2025
Expected Pipeline Expansion 3-4 new therapeutic candidates Next 24 months
Projected Revenue Growth 12-15% Annual Projection

Strategic partnership opportunities include:

  • Collaborative research agreements with leading pharmaceutical companies
  • Potential licensing deals for innovative therapeutic platforms
  • International market expansion strategies

Competitive advantages positioning the company for growth:

  • Proprietary technological platforms in targeted therapies
  • Strong intellectual property portfolio with 17 active patents
  • Experienced management team with proven track record in biotechnology sector

DCF model

Molecular Templates, Inc. (MTEM) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.